ArticlePloS one2013
Drug Promiscuity in PDB: Protein Binding Site Similarity Is Key.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it, 150 citations in OpenAlex.
- Antiangiogenic Activity of Flavonoids: A Systematic Review and Meta-Analysis.Molecules (Basel, Switzerland) · 2020Pooled it
- Trial
- Ligand-agnostic off-target site prediction for early toxicity screening by leveraging point cloud-based protein cavity analysis.Briefings in bioinformatics · 2026Article
- Similarity of drug targets to human microbiome metaproteome promotes pharmacological promiscuity.The pharmacogenomics journal · 2025Article
- Article
- Comprehensive detection and characterization of human druggable pockets through binding site descriptors.Nature communications · 2024Article
- Essential Oil Compounds of Andaliman (Life (Basel, Switzerland) · 2023Article
- Knowledge Mapping of Drug Repositioning's Theme and Development.Drug design, development and therapy · 2023Review
- Functional Heterodimerization between the G Protein-Coupled Receptor GPR17 and the Chemokine Receptors 2 and 4: New Evidence.International journal of molecular sciences · 2022Article
- The module triad: a novel network biology approach to utilize patients' multi-omics data for target discovery in ulcerative colitis.Scientific reports · 2022Article
- Classification of Protein-Binding Sites Using a Spherical Convolutional Neural Network.Journal of chemical information and modeling · 2022Article
- KUALA: a machine learning-driven framework for kinase inhibitors repositioning.Scientific reports · 2022Article
- Estimating the Similarity between Protein Pockets.International journal of molecular sciences · 2022Review
- Common Structural Pattern for Flecainide Binding in Atrial-Selective KPharmaceutics · 2022Article
- Decomposing compounds enables reconstruction of interaction fingerprints for structure-based drug screening.Journal of cheminformatics · 2022Article
- Montelukast is a dual-purpose inhibitor of SARS-CoV-2 infection and virus-induced IL-6 expression identified by structure-based drug repurposing.Computational and structural biotechnology journal · 2022Article
- Diabetes medications as potential calorie restriction mimetics-a focus on the alpha-glucosidase inhibitor acarbose.GeroScience · 2021Article
- A systems-based method to repurpose marketed therapeutics for antiviral use: a SARS-CoV-2 case study.Life science alliance · 2021Article
- Virtual screening web servers: designing chemical probes and drug candidates in the cyberspace.Briefings in bioinformatics · 2021Review
- Rapid Identification of Inhibitors and Prediction of Ligand Selectivity for Multiple Proteins: Application to Protein Kinases.The journal of physical chemistry. B · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug repositioning applies established drugs to new disease indications with increasing success. A pre-requisite for drug repurposing is drug promiscuity (polypharmacology) - a drug's ability to bind to several targets. There is a long standing debate on the reasons for drug promiscuity. Based on large compound screens, hydrophobicity and molecular weight have been suggested as key reasons. However, the results are sometimes contradictory and leave space for further analysis. Protein structures offer a structural dimension to explain promiscuity: Can a drug bind multiple targets because the drug is flexible or because the targets are structurally similar or even share similar binding sites? We present a systematic study of drug promiscuity based on structural data of PDB target proteins with a set of 164 promiscuous drugs. We show that there is no correlation between the degree of promiscuity and ligand properties such as hydrophobicity or molecular weight but a weak correlation to conformational flexibility. However, we do find a correlation between promiscuity and structural similarity as well as binding site similarity of protein targets. In particular, 71% of the drugs have at least two targets with similar binding sites. In order to overcome issues in detection of remotely similar binding sites, we employed a score for binding site similarity: LigandRMSD measures the similarity of the aligned ligands and uncovers remote local similarities in proteins. It can be applied to arbitrary structural binding site alignments. Three representative examples, namely the anti-cancer drug methotrexate, the natural product quercetin and the anti-diabetic drug acarbose are discussed in detail. Our findings suggest that global structural and binding site similarity play a more important role to explain the observed drug promiscuity in the PDB than physicochemical drug properties like hydrophobicity or molecular weight. Additionally, we find ligand flexibility to have a minor influence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.